To assess the prevalence and adequacy of warfarin use in patients with atrial fibrillation (AF) according to stroke risk, as assessed by CHADS2 scores, in a nationally representative patient sample. METHODS: The data source was GE's Medical Quality Improvement Consortium (MQIC) database (February 2009) containing electronic medical records (EMRs) data on 11 million patients in the U.S. Eligible patients were those with a diagnosis of AF, age 40 years at AF diagnosis, and with no use of warfarin or antiplatelet agents at anytime prior to AF diagnosis. Ineligible patients were those who might have other reasons, such as cancer or orthopedic surgery, to be hypercoagulable (i.e. other justifications for different anticoagulant use or INR ranges), or those already on antiplatelet agents or warfarin prior to AF diagnosis. CHADS2 stroke risk scores were assigned on the basis of conditions prior to or coincident with the AF diagnosis (congestive heart failure, hypertension, diabetes mellitus, stroke/TIA). The last INR on record was captured for all eligible patients. RESULTS: From 11,196,881 total patients, 58,848 patients with AF met all selection criteria. Patients at high risk of stroke (CHADS2 2) comprised 99% 2) comprised 99% (58,214) of the total patients. Among the high risk patients, 24,953 (43%) were on warfarin, 8,541 (15%) antiplatelet agents, and 24,720 (42%) neither. Of the 24,953 patients on warfarin, the last INR on record was in the suboptimal range ( 2) in 13,198 (53%), above optimal range ( 3) in 2,969 (12%), and in optimal range (2-3) in 8786 (35%). CONCLUSIONS: Analysis of a large, nationally representative EMR database suggests that the majority of AF patients at increased risk of stroke are receiving suboptimal anticoagulation.
PCV44 HEART FAILURE IN OLDER PEOPLE: A STUDY OF FACTORS THAT LEAD TO HOSPITALISATION
Brown SH, Abdelhafiz AH Rotherham General Hospital, Rotherham, UK OBJECTIVES: Heart failure is a frequent cause of hospitalisation among older patients. This study examines the principal factors leading to acute decompensation of heart failure leading to hospital admission and considers whether these factors are avoidable. METHODS: We conducted a retrospective casenote study of all patients admitted to the department of Geriatric Medicine over a 2 year period who had a principal discharge diagnosis of heart failure (ICD codes 428.0, 428.1, 428.9). Demographic and clinical data on medical history, clinical examination, radiographic findings, echocardiography, blood tests and medications was collected. Each case was evaluated to determine the factor that contributed most to heart failure decompensation. Main factors leading to hospitalisation included: volume overload if patient had all signs of hypervolaemia (pedal oedema, elevated jugular venous pressure, pulmonary crepitations and dilutional hyponatraemia), tachyarrhythmia if heart rate was 150 beats per minute, or uncontrolled hypertension if systolic blood pressure 180mmHg. RESULTS: The study sample included 145 patients. Mean (SD) age was 82(5) years and 74 (51%) were women. All patients were taking diuretics and 75 (51.5%) were taking angiotensin converting enzyme inhibitors. Twenty two (15.2%) were taking non steroidal anti-inflammatory drugs (NSAIDs). Risk factors for admission were identified in this rank order: volume overload 52 (35.9%) patients, chest infection 26 (17.9%) patients, combination of volume overload and chest infection 19 (13.1%) patients, myocardial infarction 17 (11.7%) patients, tachyarrhythmia (mainly atrial fibrillation) 9 (6.2%) patients, uncontrolled hypertension 10 (6.9%) and pulmonary embolus 1 (0.7%). In 11 (7.6%) patients no precipitating factor could be determined. Of the 52 patients with volume overload 12 (23.1%) were receiving NSAIDs on admission. CONCLUSIONS: Our findings show that factors leading to hospitalisation for heart failure may be amenable to intervention, particularly volume overload. Patient education regarding diet and medication, especially NSAIDs, and regular monitoring of blood pressure should be considered.
PCV45 DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL HIGH-RISK PATIENTS
Smolen HJ 1 , Klein RW 1 , Klein TM 1 , Cohen DJ 2 1 Medical Decision Modeling Inc, Indianapolis, IN, USA, 2 Saint Luke's Mid America Heart Institute, Kansas City, MO, USA OBJECTIVES: To estimate the threshold of relative stroke risk needed that makes medical management inferior to protected carotid stenting in asymptomatic patients with carotid artery stenosis and substantial cardiovascular comorbidities. METHODS: A validated and published Monte Carlo microsimulation model created a stroke-free, two-year survival curve in monthly increments for a hypothetical medically managed arm of a recent single-arm carotid revascularization trial in patients at high surgical risk due to their cardiovascular comorbidities. Using a log rank test the actual two-year survival curve from the ACCULINK for Revascularization of Carotids in High-Risk patients (ARCHeR) trial data was compared to the medically-managed curve generated by the model. The model stroke risk equations were generated from the general population and calibrated for patients with asymptomatic carotid artery stenosis but otherwise healthy. Relative stroke risks between these patients and the surgical highrisk patients were estimated from the stroke rates of the intervention arm of a trial with more restrictive inclusion criteria (ACAS) and the strokes rates of ARCHeR. RESULTS: Using the best estimate of relative risk (2.02) the one-and two-year stroke rates for medical management were 0.901 and 0.851, respectively. This compares to 0.934 and 0.879 from the ARCHeR trial using protected carotid stenting. The Chisquare statistic from the log rank test of two-year survival curves was 2.26; p 0.13 that medical management produces different results from carotid stenting. As long as the relative risk is greater than 2.25 the p value is 0.05. CONCLUSIONS: Recent carotid stenosis trials lack medically managed populations, but a model can estimate stroke-free survival and mortality data for these patients if the relative risk compared to a known population can be estimated. Since the ARCHeR trial found no ipsilateral strokes in its third year, this two-year analysis may overestimate the relative risk needed to justify carotid stenting. contrast echocardiography patients, 2,900 had diagnoses meeting criteria for critical illness (heart failure, acute myocardial infarction, arrhythmia, respiratory failure, pulmonary embolism, emphysema , and pulmonary hypertension). To control for the differences between the contrast and non-contrast patients we used propensity score matching. Variables used in the construction of the propensity score included comorbidities , demographic factors , hospital-specific factors , level of care, and mechanical ventilation status. Patients receiving contrast echocardiography were matched to 4 controls who received non-contrast echocardiography. Conditional logistic regression was used to estimate mortality effects. RESULTS: There were 167 deaths in the study among critically ill patients, 38/2900 from the contrast group and 129/11600 from the control group. The contrast agent was not associated with an increase in same-day mortality (odds ratio 1.18 (95% C.I. 0.82, 1.71); P 0.37)). Prior to matching, contrast patients showed greater morbidity then non-contrast patients (Deyo-Charlson Comorbidity Score 2.45 vs. 2.25, P 0.0001). After propensity-score matching these differences were significantly reduced, showing that both groups were well-balanced. CONCLUSIONS: There is no increase in mortality in critically ill patients undergoing echocardiography with the contrast agent compared to case-matched controls.
PCV46 PERFLUTREN PROTEIN-TYPE

PCV47 THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND ALL-CAUSE MORTALITY
Simons WR 1 , Edwards DM 2 1 Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2 Abbott Australasia, Botany, NSW, Australia OBJECTIVES: Health benefits of low-density lipoprotein cholesterol (LDL-C) at recommended levels are well known; benefits of HDL-C at recommended levels are less well documented. This study assesses and replicates the quantification of the relationship between HDL-C and all-cause mortality while aligning relative importance to LDL-C. METHODS: A comprehensive analyses of available epidemiological studies including HDL-C and all-cause mortality as an endpoint were included in a metaregression. That meta-regression was independently validated with a longitudinal analysis of an Australian epidemiological database (General Practitioner Research Network) 1999 -2008 . While statistical association is important, demonstration that modifications via intervention to the clinical measure (HDL-C) effect change in the endpoint is more important. RESULTS: Twenty-two epidemiological studies in 153,798 patients met the criteria. In a survival analysis for time to death, higher HDL-C is significantly associated with longer duration to death (P 0.043); 0.33 mmol/L higher HDL and 1.33 lower total/HDL cholesterol were each associated with about a third lower vascular mortality. Twenty-five placebo-controlled intervention trials yielded a regression that explained 83% of the variation in percent changes in cardiovascular events with parameter estimates associated with percent changes in HDL-C and LDL-C of 1.51 (P 0.02) and 1.02 (P 0.02). Alternatively, a 1% increase in HDL-C equates to a 1.5% change in cardiovascular events while a 1% reduction in LDL-C equates to a 1% reduction in those events. HDL-C is statistically significantly inversely related to mortality. Higher HDL-C is associated with a decrease in the likelihood of death ( 1.73; P 0.04) while repeated measures that are higher further decrease that probability ( 0.01: P 0.02). Lower LDL-C decreases the probability of death. CONCLUSIONS: The relationship between HDL-C and allcause mortality was quantified, replicated and validated and shown to be of greater prognostic value than LDL-C. New antithrombotic therapies have the potential to improve outcomes and decrease costs. The ACUITY and HORIZONS-AMI studies demonstrated improved clinical event rates (mortality and bleeding) using bivalirudin compared to a heparinplus-GPI regimen. This analysis evaluated the economic impact of this improvement in the German hospital setting. METHODS: A budget-impact model was developed to evaluate the impact of bivalirudin in unstable angina (UA)/non-ST-elevated myocardial infarction (NSTEMI) patients undergoing PCI in a German hospital. Clinical data for the model were derived from the ACUITY trial and included 30-day event rates for major complications (major and minor bleeding as defined by trial protocol, Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft [CABG] ). Economic data were derived from the medical literature, including clinical outcomes as well as ward costs (both regular and ICU/CCU) and pharmaceutical costs. Additional analysis using resource use data from the ADONIS registry was performed. A subgroup of high risk patients (per ESC definition) was also examined in the model. RESULTS: For UA/NSTEMI patients, overall average per procedure cost was a5347 with heparin plus GPI and a4822 with bivalirudin. In 100 PCI patients, bivalirudin use would result in 3 fewer major bleeding events (3.1%) and 11 fewer minor bleeding events (10.7%). Total hospital costs comparing 100% heparin-based strategy to 100% bivalirudin-based strategy were a341,473 and a289,025, respectively, resulting in a cost-savings with bivalirudin of a52,448 (15%). For high risk UA/NSTEMI patients the cost-savings over 100 procedures are a56,233 (16%). CONCLUSIONS: A bivalirudin-based strategy for anticoagulant use in UA/NSTEMI patients undergoing PCI is associated with favorable clinical and economic outcomes when compared with heparin plus GPI in a German hospital setting.
CARDIOVASCULAR DISORDERS -Cost
PCV49 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE
Hadker N 1 , Garg S 1 , Costanzo C 1 , Miller JD 1 , van der Helm W 2 , Foster T 1 , Creeden J 2 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Roche Diagnostics, Ltd, Rotkreuz, Switzerland OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers. Clinical and economic benefits may result from appropriate detection and management of subclinical cases, and from averting costs associated with incorrect diagnoses. We evaluated the financial impact of the novel test versus standard care from a German health care payer perspective.
METHODS:
We developed a decision-analytic model of the clinical and economic impact resulting from improved sensitivity and specificity of the new test over current diagnostic practice. Acute management and follow-up costs were associated with true positive, true negative, false positive, and false negative diagnoses. The base-case analysis assumed that, of all pregnant women, 10% present with risk factors while 90% do not. The CHF 52 (a-equivalent) test was assumed to be administered after 20 weeks of gestation. True positive and false negative patients were assumed to enter one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; or death. Data pertaining to treatment practices, health care resource utilization, incidence, costs, and funding for detection and management of preeclampsia in Germany were obtained through interviews with clinicians, laboratory managers, and health care payers in Germany. Additional data were obtained from published literature and public databases. RESULTS: Model results suggest that when used for screening, the novel test would reduce false negative diagnoses of preeclampsia by 67% and false positives by 71%. Costs per patient are estimated to be a941 with the novel test and a1578 with standard practice, saving an estimated a637 per patient given the novel test. CONCLUSIONS: This test has the potential to improve detection and management of preeclampsia translating into substantial cost savings for German health care payers.
PCV50 BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN UK HOSPITALS
Olchanski N 1 , Slawsky K 1 , Cyr PL 1 , Schwenkglenks M 2 , Kinnaird T 3 1 Boston Healthcare Associates, Inc., Boston, MA, USA, 2 University of Basel, Basel, Switzerland, 3 University Hospital of Wales, Cardiff, UK OBJECTIVES: Approximately 5900 PPCIs were performed in the UK in 2007. This number is expected to double in the next 5 years post the 2008 NIAP report. New antithrombotic therapies have the potential to improve clinical outcomes and decrease costs. The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event rates (mortality and bleeding) compared to a heparin and GPI (HEP GPI) regimen. The potential economic value of implementing bivalirudin in the PPCI setting is evaluated in this analysis from the UK hospital perspective. METHODS: A budget impact model was developed to compare treatment of STEMI patients undergoing PPCI with either bivalirudin or HEP GPI. Clinical data for the model was derived from the HORIZONS trial, and included 30-day event rates for major complications (major and minor bleeding as defined by trial protocol, Q-wave myocardial infarction [MI] , and repeat PCI and coronary artery bypass graft [CABG] procedures). UK cost and clinical practice data were derived from published sources. RESULTS: Overall average procedure cost per bivalirudin-treated patient (incorporating 7.2% provisional GPI use as per HORIZONS) was £4284, compared to £5015 per HEP GPI-treated patient. In extrapolating these benefits to a typical NHS hospital of 200 PPCI patients per year, 7 major bleeding events (3.4%), 13 minor bleeding events (6.6%), and 2 deaths (1%) in patients would be averted if treated with bivalirudin. The total hospital budget impact of treating 200 PPCI patients using a HEP GPI based strategy is £1,002,913. Introducing a bivalirudin-based strategy could save £146,129 (15%) per year. CON-CLUSIONS: Using a bivalirudin-based strategy in STEMI patients undergoing PPCI is associated with favorable clinical and economic outcomes when compared with HEP GP in a UK hospital setting.
PCV51 THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY
Jackson D 1 , Moshinsky J 2 , Begg A 2 1 GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, 2 Medaxial Group, London, UK OBJECTIVES: Due to a lack of awareness of Transient Ischaemic Attack (TIA) symptoms, many patients may not immediately seek medical help, creating a delay in access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007; 370:1432-42 ) demonstrated that greater focus on effectively managing TIA could have a significant impact on subsequent stroke rates. With nearly 200,000 strokes occurring in Italy each year, we wanted to examine how a shift in care pathways towards that outlined in phase 2 of the EXPRESS study could affect rates of stroke, and explore the financial implications of such a shift in care pathway. METHODS: We developed an economic model to estimate the costs and savings associated with establishing a rapid assessment and treatment clinic for patients with suspected TIA in Italy, in line with phase 2 of the EXPRESS study. We used a population of 1,000,000 people with an assumed annual incidence of TIA of 0.058%. Current management was based on ESO guidelines and common clinical practice. We included direct costs associated with care (medications, diagnostics and staff-where data were unavailable, UK converted costs were used), and modelled the impact of changing management over three years. RESULTS: For a population of 1,000,000, changing the pathway of care to ensure rapid assessment and treatment for TIA patients would result in 180 future stroke events being avoided over three years. As a result, additional costs associated with changing the TIA pathway of care were offset by savings generated through avoiding acute stroke management costs. CONCLUSIONS: Our model suggests that implementing a revised TIA care pathway in Italy would be cost saving. For a local population of 1,000,000, savings associated with the avoidance of acute stroke management would offset the costs of establishing rapid assessment and treatment clinics for patients experiencing TIA.
PCV52 RECONFIGURING TIA CARE PATHWAYS IN HUNGARY: AVOIDING RECURRENT STROKE
Jackson D 1 , Moshinsky J 2 , Begg A 2 1 GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, 2 Medaxial Group, London, UK OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symptoms, many patients may not immediately seek medical help, creating a delay in access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007; 370:1432-42) demonstrated that greater focus on rapid assessment and management of TIA could significantly reduce subsequent stroke rates. With over 42,000 hospitalisations due to strokes in Hungary each year, we wanted to examine how a shift in care pathways towards that outlined in the EXPRESS study could affect stroke rates, and explore the financial implications of such a shift in care pathway. METHODS: We developed an economic model to estimate the costs and savings associated with establishing a rapid assessment and treatment clinic for patients with suspected TIA in Hungary, in line with phase 2 of the EXPRESS study. We used a population of 1,000,000 with an assumed annual TIA incidence of 0.042%. Current management was based on ESO guidelines and common clinical practice. We included direct costs associated with secondary care (medications, diagnostics and staff-where data were unavailable, converted UK costs were used), and modelled the impact of changing management over a three-year time horizon. RESULTS: For a population of 1,000,000, changing
